e-Library of Evidence for Nutrition Actions (eLENA)


An online library of evidence-informed guidelines for nutrition interventions and single point of reference for the latest nutrition guidelines, recommendations and related information.

Alternate Text All interventions

Deworming in pregnant women

Intervention | Last updated: 20 June 2023


Soil-transmitted helminth infections are among the most common infections in humans, caused by a group of parasites commonly referred to as worms, including roundworms, whipworms and hookworms. Those living in poverty are most vulnerable to infection which can impair nutritional status by causing:

  • internal bleeding which can lead to loss of iron and anaemia;
  • intestinal inflammation and obstruction;
  • diarrhoea; and
  • impairment of nutrient intake, digestion and absorption.

Evidence shows that preventive chemotherapy, or the periodic large-scale administration of anthelminthic medicines to populations at risk, can dramatically reduce the burden of worms caused by soil-transmitted helminth infections.

Preventive chemotherapy is an important part of a comprehensive package to eliminate morbidity due to soil-transmitted helminths in at-risk populations. However, long-term solutions to soil-transmitted helminth infections will need to address many factors, including improvements in water, sanitation and hygiene.

WHO Recommendations


Preventive chemotherapy (deworming), using single-dose albendazole (400 mg) or mebendazole (500 mg), is recommended as a public health intervention for pregnant women, after the first trimester, living in areas where both: (i) the baseline prevalence of hookworm and/or T. trichiura infection is 20% or more among pregnant women, and (ii) where anaemia is a severe public health problem, with a prevalence of 40% or higher among pregnant womena, in order to reduce the worm burden of hookworm and T. trichiura infection.

a For the most recent estimates of prevalence of anaemia, visit the WHO-hosted Vitamin and Mineral Nutrition Information System (VMNIS).

This recommendation is consistent with that found in the 2016 WHO recommendations on antenatal care for a positive pregnancy experience (see 'WHO documents' below).



Cost-effectiveness Learn More Alternate Text


Relevant cost-effectiveness analyses have not yet been identified.